Methods and compositions for treating mucosal tissue disorders
AssigneeThe University of North Carolina at Chapel Hill
InventorsRoland R. Arnold, David C. Henke
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and formulations comprising glutathione with or without thiocyanate and methods of use thereof to treat diseases and disorders in mucosal/epithelial tissue.
Claims36
A method for reducing the onset and/or progression of bacterial growth in a subject's airway, comprising prophylactically administering by inhalation to the airway of the subject an effective amount of a composition comprising:
- a) a glutathione, or a pharmaceutically-acceptable salt of glutathione;
- b) an organic acid or a pharmaceutically-acceptable salt of an organic acid;
- and
- c) a carrier,
- wherein the subject suffers from a pulmonary or airway disorder or disease selected from the group consisting of an inflammatory lung disease and/or infection of the lung, inflammation and/or infection associated with lung transplantation, acute lung rejection, asthma, cystic fibrosis, chronic obstructive pulmonary disease (COPD), and any combination thereof.
A method for reducing the onset and/or progression of bacterial growth in a subject in need thereof, comprising prophylactically administering by inhalation to the airway of the subject prior to a surgical procedure, intubation, mechanical ventilation, or post-operatively an effective amount of a composition comprising:
- a) a glutathione, or a pharmaceutically-acceptable salt of glutathione;
- b) an organic acid or a pharmaceutically-acceptable salt of an organic acid;
- and
- c) a carrier.
A method for establishing and/or maintaining homeostasis in the mucosal tissue of a subject's airway, comprising prophylactically administering by inhalation to the airway of the subject an effective amount of a composition comprising:
- a) a glutathione, or a pharmaceutically-acceptable salt of glutathione;
- b) an organic acid or a pharmaceutically-acceptable salt of an organic acid;
- and
- c) a carrier,
- wherein the subject suffers from a pulmonary or airway disorder or disease selected from the group consisting of an inflammatory lung disease and/or infection of the lung, inflammation and/or infection associated with lung transplantation, acute lung rejection, asthma, cystic fibrosis, chronic obstructive pulmonary disease (COPD), and any combination thereof.
Dependencies are inferred from the claim text.